498 lines
No EOL
103 KiB
HTML
498 lines
No EOL
103 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK65898" /><meta name="ncbi_domain" content="pdqcis" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK65898.5/" /><meta name="ncbi_pagename" content="Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]" /><meta name="citation_title" content="Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2017/02/03" /><meta name="citation_author" content="PDQ Screening and Prevention Editorial Board" /><meta name="citation_pmid" content="26389336" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65898/" /><meta name="citation_keywords" content="ovarian epithelial cancer" /><meta name="citation_keywords" content="fallopian tube cancer" /><meta name="citation_keywords" content="primary peritoneal cavity cancer" /><meta name="citation_keywords" content="disease screening" /><meta name="citation_keywords" content="disease screening" /><meta name="citation_keywords" content="fallopian tube cancer" /><meta name="citation_keywords" content="ovarian epithelial cancer" /><meta name="citation_keywords" content="primary peritoneal cavity cancer" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="PDQ Screening and Prevention Editorial Board" /><meta name="DC.Date" content="2017/02/03" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65898/" /><meta name="description" content="Expert-reviewed information summary about tests used to detect or screen for ovarian, fallopian tube, and primary peritoneal cancers." /><meta name="og:title" content="Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)" /><meta name="og:type" content="book" /><meta name="og:description" content="Expert-reviewed information summary about tests used to detect or screen for ovarian, fallopian tube, and primary peritoneal cancers." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65898/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062760/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65898/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8EA8267C9849410000000000CC009E.m_13" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
<div id="universal_header">
|
|
<section class="usa-banner">
|
|
<div class="usa-accordion">
|
|
<header class="usa-banner-header">
|
|
<div class="usa-grid usa-banner-inner">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
|
<p>An official website of the United States government</p>
|
|
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
|
<span class="usa-banner-button-text">Here's how you know</span>
|
|
</button>
|
|
</div>
|
|
</header>
|
|
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
|
<div class="usa-banner-guidance-gov usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The .gov means it's official.</strong>
|
|
<br />
|
|
Federal government websites often end in .gov or .mil. Before
|
|
sharing sensitive information, make sure you're on a federal
|
|
government site.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The site is secure.</strong>
|
|
<br />
|
|
The <strong>https://</strong> ensures that you are connecting to the
|
|
official website and that any information you provide is encrypted
|
|
and transmitted securely.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<div class="usa-overlay"></div>
|
|
<header class="ncbi-header" role="banner" data-section="Header">
|
|
|
|
<div class="usa-grid">
|
|
<div class="usa-width-one-whole">
|
|
|
|
<div class="ncbi-header__logo">
|
|
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ncbi-header__account">
|
|
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
|
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
|
<span class="fa fa-user" aria-hidden="true">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
|
<g style="fill: #fff">
|
|
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
|
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
|
</g>
|
|
</svg>
|
|
</span>
|
|
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
|
<span class="sr-only">Show account info</span>
|
|
</button>
|
|
</div>
|
|
|
|
<div class="ncbi-popup-anchor">
|
|
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
|
<div class="ncbi-popup-head">
|
|
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
|
<span class="fa fa-times">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
|
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
|
</svg>
|
|
</span>
|
|
<span class="usa-sr-only">Close</span></button>
|
|
<h4>Account</h4>
|
|
</div>
|
|
<div class="account-user-info">
|
|
Logged in as:<br />
|
|
<b><span class="username" id="uname_long">username</span></b>
|
|
</div>
|
|
<div class="account-links">
|
|
<ul class="usa-unstyled-list">
|
|
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
|
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
|
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
|
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</div>
|
|
</header>
|
|
<div role="navigation" aria-label="access keys">
|
|
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
|
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
|
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
|
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
|
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
|
</div>
|
|
<section data-section="Alerts">
|
|
<div class="ncbi-alerts-placeholder"></div>
|
|
</section>
|
|
</div>
|
|
<div class="header">
|
|
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
|
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="nlmcatalog">NLM Catalog</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
|
<a href="/books/browse/">Browse Titles</a>
|
|
</li><li>
|
|
<a href="/books/advanced/">Advanced</a>
|
|
</li><li class="help">
|
|
<a href="/books/NBK3833/">Help</a>
|
|
</li><li class="disclaimer">
|
|
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
|
</li></ul></div>
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<!-- Custom content 1 -->
|
|
<div class="col1">
|
|
|
|
</div>
|
|
|
|
<div class="container">
|
|
<div id="maincontent" class="content eight_col col">
|
|
<!-- Custom content in the left column above book nav -->
|
|
<div class="col2">
|
|
|
|
</div>
|
|
|
|
<!-- Book content -->
|
|
|
|
|
|
<!-- Custom content between navigation and content -->
|
|
<div class="col3">
|
|
|
|
</div>
|
|
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/pdqcis/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" alt="Cover of PDQ Cancer Information Summaries" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>PDQ Cancer Information Summaries [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK65898_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK65898_dtls__"><div>Bethesda (MD): <a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2002-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/pdqcis/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK65898_"><span class="title" itemprop="name">Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contrib-group"><span itemprop="author">PDQ Screening and Prevention Editorial Board</span>.</p><p class="small">Published online: February 3, 2017.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062760__172">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian, fallopian tube, and primary peritoneal cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062760__173">This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062760__1"><h2 id="_CDR0000062760__1_">Overview</h2><p id="CDR0000062760__2">Note: Separate PDQ summaries on <a href="/books/n/pdqcis/CDR0000062771/">Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention</a>; <a href="/books/n/pdqcis/CDR0000062829/">Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment</a>; <a href="/books/n/pdqcis/CDR0000062935/">Ovarian Germ Cell Tumor Treatment</a>; and <a href="/books/n/pdqcis/CDR0000062941/">Ovarian Low
|
|
Malignant Potential Tumor Treatment</a> are also available.</p><div id="CDR0000062760__35"><h3>Evidence of Lack of Mortality Benefit Associated with Screening</h3><div id="CDR0000062760__105"><h4>Single-threshold cancer antigen 125 (CA-125) levels and transvaginal ultrasound (TVU)</h4><p id="CDR0000062760__134">There is solid evidence to indicate that screening women aged 55 to 74 years at average risk of developing ovarian cancer with the serum marker CA-125 (at a fixed threshold for a positive result of 35 U/mL) annually for 6 years and TVU for 4 years does not result in a decrease in ovarian cancer mortality, after a median follow-up of 14.7 years.</p><p id="CDR0000062760__135"><b>Magnitude of Effect: The ovarian cancer mortality rate was 3.8 deaths per 10,000 women in the screened group and 3.6 deaths per 10,000 person-years in the usual-care group, yielding a mortality rate ratio of 1.06 (95% confidence interval [CI], 0.87–1.30).[<a class="bk_pop" href="#CDR0000062760_rl_1_1">1</a>]</b></p><ul id="CDR0000062760__136" class="simple-list"><li class="half_rhythm"><div><b>Study Design</b>: Evidence obtained from one randomized controlled trial.</div></li><li class="half_rhythm"><div><b>Internal Validity</b>: Good.</div></li><li class="half_rhythm"><div><b>Consistency</b>: One trial has evaluated the impact on mortality from ovarian cancer.</div></li><li class="half_rhythm"><div><b>External Validity</b>: Good.</div></li></ul></div><div id="CDR0000062760__189"><h4>Screening with TVU alone or with multimodal screening with CA-125 levels, assessed using the Risk of Ovarian Cancer Algorithm (ROCA), with TVU</h4><p id="CDR0000062760__190">Screening with TVU alone or with multimodal screening with CA-125 levels, assessed using the ROCA, combined with TVU in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) did not show a mortality benefit of screening with either approach based on a predetermined primary endpoint among women undergoing 7 to 11 screens and a median of 11.1 years of follow-up.[<a class="bk_pop" href="#CDR0000062760_rl_1_2">2</a>]</p><p id="CDR0000062760__191"><b>Magnitude of Effect: Multimodal screening was associated with a nonsignificantly lower mortality than with no screening (15% lower mortality; 95% CI, -3% to 30%; <i>P</i> = .10). Ultrasound only screening also resulted in nonsignificantly lower mortality (11% lower mortality; 95% CI, -7% to 27%; <i>P</i> = .21).[<a class="bk_pop" href="#CDR0000062760_rl_1_2">2</a>]</b></p><ul id="CDR0000062760__192" class="simple-list"><li class="half_rhythm"><div>Screening complications were less than 1% for both TVU only and multimodality screening strategies.</div></li><li class="half_rhythm"><div><b>Study Design</b>: Evidence obtained from one randomized controlled trial.</div></li><li class="half_rhythm"><div><b>Internal Validity</b>: Good.</div></li><li class="half_rhythm"><div><b>Consistency</b>: One trial has evaluated the impact on mortality from ovarian cancer using this specific approach.</div></li><li class="half_rhythm"><div><b>External Validity</b>: Good—based on data from other studies assessing complementary endpoints.</div></li></ul></div><div id="CDR0000062760__193"><h4>Statement of Harms</h4><p id="CDR0000062760__194">Based on solid evidence, screening for ovarian cancer results in false-positive test results. Screened women had higher rates of oophorectomy and other minor complications such as fainting and bruising.</p><p id="CDR0000062760__195"><b>Magnitude of Effect: </b></p><ul id="CDR0000062760__196" class="simple-list"><li class="half_rhythm"><div>Of screened women, 9.6% had false-positive results, resulting in 6.2% undergoing surgery. The surgical complication rate was 1.2% for all screened women.</div></li><li class="half_rhythm"><div>Oophorectomy rates were 85.7 per 10,000 person-years among screened women and 64.2 per 10,000 person-years among usual-care women.</div></li><li class="half_rhythm"><div> Minor complications with screening: 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with transvaginal sonogram (TVS).</div></li><li class="half_rhythm"><div><b>Study Design</b>: Evidence obtained from one randomized controlled trial.</div></li><li class="half_rhythm"><div><b>Internal Validity</b>: Good.</div></li><li class="half_rhythm"><div><b>Consistency</b>: Not applicable (N/A).</div></li><li class="half_rhythm"><div><b>External Validity</b>: Good. </div></li></ul><p id="CDR0000062760__197">In the TVU-only arm of the UKCTOCS trial, there were 50 false-positive surgical procedures, and in the multimodality arm, there were 14 false-positive operations per 10,000 screens.[<a class="bk_pop" href="#CDR0000062760_rl_1_2">2</a>]</p><p id="CDR0000062760__198">In the general population, screening is targeted to postmenopausal women, and the major complications are related to surgery. Among younger women, the potential target group among <i>BRCA1/2</i> mutation carriers, oophorectomy at younger than 45 years may increase mortality secondary to cardiovascular disease. Oophorectomy, if performed among younger women, may also reduce risk of estrogen receptor–positive breast cancers, which occur with elevated frequency among carriers of <i>BRCA2</i> mutations.</p></div></div><div id="CDR0000062760_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062760_rl_1_1">Buys SS, Partridge E, Black A, et al.: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305 (22): 2295-303, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21642681" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21642681</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_1_2">Jacobs IJ, Menon U, Ryan A, et al.: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387 (10022): 945-56, 2016. [<a href="/pmc/articles/PMC4779792/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4779792</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26707054" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26707054</span></a>]</div></li></ol></div></div><div id="CDR0000062760__7"><h2 id="_CDR0000062760__7_">Description of the Evidence</h2><div id="CDR0000062760__8"><h3>Background</h3><div id="CDR0000062760__107"><h4>Incidence and mortality</h4><p id="CDR0000062760__108">Ovarian carcinoma is the fifth leading cause of cancer death among women in the United States and
|
|
has the highest mortality rate of all gynecologic cancers. It is estimated that 22,440 new cases of ovarian cancer will be diagnosed in the United States in 2017, and 14,080 women will
|
|
die of this disease. Over the last 20 years, incidence rates decreased by 1% per year in white women and by 0.4% per year in African American women. From 2005 to 2014, mortality rates decreased by 2% per year in white women and by 1% per year in African American women.[<a class="bk_pop" href="#CDR0000062760_rl_7_1">1</a>] The prognosis for survival from ovarian carcinoma largely depends on stage, which is strongly associated with histopathologic type. Approximately 75% of women with ovarian carcinoma have high-grade serous carcinoma, of which 90% present with stage III or IV disease, leading to poor survival.[<a class="bk_pop" href="#CDR0000062760_rl_7_1">1</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_2">2</a>] </p><p id="CDR0000062760__110">Ovarian cancer is rare; the lifetime risk of being diagnosed with ovarian cancer is 1.31%.[<a class="bk_pop" href="#CDR0000062760_rl_7_2">2</a>]</p></div></div><div id="CDR0000062760__27"><h3>Types of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer</h3><p id="CDR0000062760__45">The term <i>ovarian cancer</i> encompasses a heterogeneous group of malignant tumors of ovarian origin that may arise from germ cells, stromal tissue, or epithelial tissue within the ovary. Epithelial cancers are the most common type of ovarian cancer and are further classified into five main types: high-grade serous, endometrioid, clear cell, mucinous, and low-grade serous carcinomas.[<a class="bk_pop" href="#CDR0000062760_rl_7_3">3</a>] Data from detailed pathology reviews of specimens removed during risk-reducing surgery from carriers of mutations in <i>BRCA1</i>/<i>BRCA2</i> have demonstrated a putative precursor of high-grade serous carcinoma in the fimbria of the fallopian tube (serous tubal intraepithelial carcinoma [STIC]), suggesting that many carcinomas in this group previously classified as ovarian are actually tubal primary tumors. Similar lesions have been found in noncarriers of <i>BRCA1/2</i> mutations, but most data from this group are limited by the presence of concurrent bulky carcinomas throughout the pelvis. STIC is not found in all cases of high-grade serous carcinoma, suggesting other possible origins of these tumors. Many endometrioid and clear cell carcinomas are postulated to arise from endometriosis, a benign lesion that may result from implantation and persistence of exfoliated menstrual endometrium. </p><p id="CDR0000062760__161">Malignant germ cell tumors and stromal tumors such as granulosa cell tumors are rare and account for 10% or less of malignant ovarian tumors.[<a class="bk_pop" href="#CDR0000062760_rl_7_4">4</a>]</p></div><div id="CDR0000062760__153"><h3>Risk Factors</h3><p id="CDR0000062760__154">For a complete description of factors associated with an increased or decreased risk of ovarian cancer, refer to the <a href="/books/n/pdqcis/CDR0000062771/#CDR0000062771__15">Factors With Adequate Evidence of an Increased Risk of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer</a> section in the PDQ summary on <a href="/books/n/pdqcis/CDR0000062771/">Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention</a> for more information. Several cancer family syndromes, such as <i>BRCA1</i> and <i>BRCA2</i> hereditary breast-ovarian syndrome and Lynch syndrome are associated with a marked increased risk of ovarian cancer.[<a class="bk_pop" href="#CDR0000062760_rl_7_4">4</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_5">5</a>] (Refer to the <a href="/books/n/pdqcis/CDR0000062855/#CDR0000062855__15">Autosomal Dominant Inheritance of Breast and Gynecologic Cancer Predisposition</a> section in the PDQ summary on <a href="/books/n/pdqcis/CDR0000062855/">Genetics of Breast and Gynecologic Cancers</a> for more information about these syndromes and other genetic risk factors for ovarian cancer.)</p></div><div id="CDR0000062760__113"><h3>Evidence of Lack of Mortality Benefit Associated With Different Screening Modalities</h3><p id="CDR0000062760__157">Ovarian cancer often presents with persistent but vague symptoms, usually occurring after the cancer has metastasized. Some investigators have proposed the use of symptom indices as a method of screening for ovarian cancer.[<a class="bk_pop" href="#CDR0000062760_rl_7_6">6</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_7">7</a>] Because this is not, by definition, asymptomatic screening, it is not considered further in this summary.</p><p id="CDR0000062760__115">Gynecologic examination usually includes a manual pelvic examination, but this procedure is commonly viewed as lacking sensitivity for detection of early-stage disease.[<a class="bk_pop" href="#CDR0000062760_rl_7_8">8</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_9">9</a>] There is no evidence for the benefit of this test for the early detection of and decreased mortality from ovarian cancer and it is not further considered.</p><p id="CDR0000062760__158">Other screening tests include transvaginal ultrasound (TVU) and the serum cancer antigen 125 (CA-125) assay. These are often performed in combination. Several biomarkers with potential application to ovarian cancer screening are under development but have not yet been validated or evaluated for efficacy in early detection and mortality reduction. </p><p id="CDR0000062760__204">A <a href="https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm519413.htm" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">U.S. Food and Drug Administration Safety Communication</a> issued in September 2016 recommends against using currently offered screening tests to screen for ovarian cancer in any population of women. Asymptomatic high-risk women who have a false-negative screening test may delay effective preventive treatments.</p><div id="CDR0000062760__117"><h4>The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)</h4><p id="CDR0000062760__118">TVU (or transvaginal sonogram [TVS]) has been proposed as a screening method for ovarian cancer because of its ability to reliably measure ovarian size and detect small masses.[<a class="bk_pop" href="#CDR0000062760_rl_7_10">10</a>] </p><p id="CDR0000062760__181">In the UKCTOCS (<a href="http://cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=285690" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCT00058032</a>), outcomes among 50,623 postmenopausal women aged 50 to 74 years who were randomly assigned to 7 to 11 rounds of annual screening with TVU alone and 50,264 who underwent multimodal screening with CA-125 testing and TVU (see below) were compared with results among 101,299 women who were not screened, which served as a comparison group. Women were recruited in 13 trial centers across the United Kingdom from 2001 to 2005. After trial initiation, but before analysis, the protocol was amended twice: 1) the study was extended to achieve greater power and 2) criteria for referral in the multimodal arm were liberalized to increase the percentage of positive screens.[<a class="bk_pop" href="#CDR0000062760_rl_7_11">11</a>]</p><p id="CDR0000062760__183">TVUs were scored as normal, resulting in continued annual screening; intermediate, leading to repeat CA-125 and TVU at 3 months; or abnormal, requiring repeat testing within 6 weeks. In the TVU arm, 314 cancers were diagnosed and 154 ovarian cancer–related deaths occurred compared with the nonscreened arm, in which 630 cancers were diagnosed and 347 ovarian cancer–related deaths occurred. Mortality was nonsignificantly lower with TVU screening (11%; 95% CI, -7% to 27%; <i>P</i> = .21). TVU screening resulted in 50 surgeries per 10,000 women for a false-positive screen. Complications resulted from less than 1% of screens and 3.4% of operations. Over a median of 11.1 years, ovarian cancer deaths occurred among 0.30% of screened women and 0.34% of unscreened women.[<a class="bk_pop" href="#CDR0000062760_rl_7_11">11</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_12">12</a>]</p></div><div id="CDR0000062760__121"><h4>CA-125 serum testing for ovarian cancer screening</h4><p id="CDR0000062760__122">CA-125 is a tumor-associated antigen that is used clinically to monitor patients with epithelial ovarian carcinomas.[<a class="bk_pop" href="#CDR0000062760_rl_7_13">13</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_14">14</a>] Measurement of CA-125 concentrations has been proposed as a potential marker for the early detection of ovarian cancer, either as a single test with a threshold cutpoint or in algorithms examining the change in levels over time. The two randomized trials have included CA-125 either in parallel or sequentially with TVU for multimodality screening. The most commonly reported CA-125 reference value that designates a positive screening test is 35 U/mL, and this was the reference value used in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial (<a href="https://clinicaltrials.gov/ct2/show/NCT01696994" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCT01696994</a>) to define an abnormal test result. The measurement of CA-125 levels, in parallel combination with TVU,[<a class="bk_pop" href="#CDR0000062760_rl_7_15">15</a>] is the ovarian screening intervention evaluated in the PLCO trial.[<a class="bk_pop" href="#CDR0000062760_rl_7_16">16</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_17">17</a>] Elevated CA-125 levels are not specific to ovarian cancer and have been observed in patients with nongynecological cancers,[<a class="bk_pop" href="#CDR0000062760_rl_7_14">14</a>] endometriosis,[<a class="bk_pop" href="#CDR0000062760_rl_7_18">18</a>] liver disease, congestive heart failure, pleural or peritoneal fluid accumulation, and in the first trimester of pregnancy.[<a class="bk_pop" href="#CDR0000062760_rl_7_19">19</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_20">20</a>] The sensitivity of the CA-125 test for the detection of ovarian cancer was estimated in two nested case-control studies using serum banks.[<a class="bk_pop" href="#CDR0000062760_rl_7_21">21</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_22">22</a>] The sensitivity for CA-125 levels of at least 35 U/mL ranged from 20% to 57% for cases occurring within the first 3 years of follow-up; the specificity was 95%. </p><p id="CDR0000062760__123">A phase II/III biomarker study was conducted to evaluate the sensitivity of several markers of ovarian cancer, including CA-125 concentrations, using specimens collected from ovarian cancer patients at four sites. The estimated sensitivity for early-stage disease (stage I and II ovarian cancer) was 56% (95% confidence interval [CI], 49%–72%) for a cutpoint set to obtain a fixed specificity of 95%. The threshold for the cutpoint for CA-125 at 95% specificity was 24 U/mL. For all cases (56% of cases had stage III or IV disease at diagnosis), the sensitivity was 73% (95% CI, 64%–84%). When the clinical cutpoint of 35 U/mL was used, the sensitivity decreased.[<a class="bk_pop" href="#CDR0000062760_rl_7_23">23</a>]</p></div><div id="CDR0000062760__126"><h4>The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Single-threshold CA-125 levels and TVU</h4><p id="CDR0000062760__127">The PLCO trial evaluated the effect of screening on ovarian cancer mortality among women aged 55 to 74 years on the basis of six annual screens with serum CA-125 testing at a threshold for positive of 35 U/mL and four annual screens with TVU. Women were randomly assigned to screening (n = 39,105) or usual care (n = 39,111) at ten screening centers across the United States between November 1993 and July 2001. Participants and their health care practitioners
|
|
received the screening test results and managed evaluation of abnormal results.
|
|
The usual-care group was not offered screening with CA-125 or TVU but received their usual medical care. Participants were initially monitored for a maximum of 13 years (median, 12.4 years; range, 10.9–13.0 years)
|
|
for cancer diagnoses and death until February 28, 2010. Mortality from ovarian cancer, including primary peritoneal and fallopian tube cancers, was the main outcome measure. Secondary outcomes included ovarian cancer incidence
|
|
and complications associated with screening examinations and diagnostic procedures.[<a class="bk_pop" href="#CDR0000062760_rl_7_24">24</a>] After transition of PLCO trial participants to a centralized follow-up process, follow-up for mortality was extended until the end of 2012, for a maximum of 19.2 years and a median of 14.7 years.[<a class="bk_pop" href="#CDR0000062760_rl_7_25">25</a>]</p><p id="CDR0000062760__128">Compliance with screening ranged from 85% at the initial round to 73% at the sixth round, while contamination in the usual-care group ranged from about 3.0% for CA-125 to 4.6% for TVU. Across the first four screening rounds, 11.1% of women had at least one positive test, 8.1% had at least one positive TVU, and 3.4% had at least one positive CA-125 test. The yields of both tests were similar. Ovarian cancer was diagnosed in 212 women (5.7 per 10,000 person-years) in the intervention group and 176 women (4.7 per 10,000 person-years) in the usual-care group (rate ratio, 1.21; 95% CI, 0.99–1.48). The stage distributions were similar by study group, with stage III and IV cancers comprising the majority of cases in both the intervention group (163 cases, 77%) and the usual-care group (137 cases, 78%). The cancer case treatment distributions were very similar between groups within each stage. Through the original period of follow-up (maximum, 13 years), 118 deaths were caused by ovarian cancer (3.1 per 10,000 person-years) in the intervention group and
|
|
100 deaths were caused by ovarian cancer (2.6 per 10,000 person-years) in the usual-care group (mortality rate ratio, 1.18;
|
|
95% CI, 0.82–1.71). Through the extended follow-up period (median, 14.7 years; maximum, 19.2 years), 187 deaths were caused by ovarian cancer (3.8 per 10,000 person-years) in the intervention group and 176 deaths were caused by ovarian cancer (3.6 per 10,000 person-years) in the usual-care group (mortality rate ratio, 1.06; 95% CI, 0.87–1.30).[<a class="bk_pop" href="#CDR0000062760_rl_7_25">25</a>] Of the 3,285 women with false-positive results, 1,080 underwent surgical
|
|
follow-up. Of the 1,080 women who underwent surgical follow-up, 163 women experienced at least one serious complication (15%). A total of 1,771 women in the intervention group (7.7%) and 1,304 in the usual-care group (5.8%) reported oophorectomy.
|
|
There were 2,924 deaths resulting from other causes (excluding ovarian, colorectal, and lung cancer)
|
|
(76.6 per 10,000 person-years) in the intervention group and 2,914 such deaths (76.2 per
|
|
10,000 person-years) in the usual-care group (rate ratio, 1.01; 95% CI, 0.96–1.06).[<a class="bk_pop" href="#CDR0000062760_rl_7_24">24</a>,<a class="bk_pop" href="#CDR0000062760_rl_7_26">26</a>]</p><p id="CDR0000062760__184">In the PLCO trial, women with visualized ovaries were at slightly higher risk of ovarian cancer (hazard ratio, 1.42; 95% CI, 1.00–2.01) than were women who had nonvisualized ovaries.[<a class="bk_pop" href="#CDR0000062760_rl_7_27">27</a>] A nested analysis found that ovarian volume increases were detectable 1 to 2 years before diagnosis, but the magnitude of change did not appear translatable to clinical management. Thus, among women in the general U.S. population, simultaneous screening with CA-125 and TVU did not reduce ovarian cancer mortality when compared with usual care.[<a class="bk_pop" href="#CDR0000062760_rl_7_24">24</a>]</p><p id="CDR0000062760__188">The Shizuoka Cohort Study of Ovarian Cancer Screening randomly assigned women to either a screening group (n = 41,668) or a control group (n = 40,799) between 1985 and 1999 at 212 hospitals in the Shizuoka prefecture of Japan. The screening protocol comprised ultrasound and CA-125 tests annually. Women with abnormal findings were referred to a gynecological oncologist. Ovarian cancer diagnoses were determined by record linkage to the Shizuoka Cancer Registry in 2002. The annual death certificate file in Shizuoka was checked to ascertain vital status. The mean follow-up time was 9.2 years, and the mean number of screens per woman was 5.4. There were 35 ovarian cancers detected in the screening group and 32 in the control group, with a nonstatistically significant difference in the stage distribution. Nine percent of regular screening attendees had at least one false-positive result.[<a class="bk_pop" href="#CDR0000062760_rl_7_28">28</a>] Mortality results from this trial are not available.</p></div><div id="CDR0000062760__131"><h4>Ovarian cancer screening using CA-125 analyzed according to the Risk of Ovarian Cancer Algorithm (ROCA) for a positive test result in combination with TVU</h4><p id="CDR0000062760__186">The UKCTOCS trial evaluated longitudinal CA-125 measurements using the ROCA, which defines a positive test as a statistically significant increase in a woman’s serial measurements based on the algorithm, irrespective of the absolute level. The goal of this approach is to detect cancers earlier by identifying subtle within-person changes. The UKCTOCS multimodal screen incorporated a two-stage approach with ROCA as the primary screen and TVS as a secondary screen (based on results of the ROCA) for its impact on ovarian cancer mortality compared with observation without screening. Of 50,078 women in the multimodality screening arm, 338 were diagnosed with ovarian cancer and 148 died of the disease. Multimodal screening detected 40% of ovarian cancers at stage I, II, or IIIA, whereas in the arm without screening, 26% were diagnosed at these stages (<i>P</i> < .0001). In this arm, less than 1% of screens led to complications and 3.1% of women developed surgical complications. Using multimodal screening, 14 per 10,000 screens led to surgery for a false-positive result. At the median follow-up of 11.1 years, there were 0.29% deaths with this screening method as compared with 0.34% in the observation arm. The primary endpoint of mortality reduction with screening based on Cox regression analysis indicated a statistically nonsignificant mortality reduction of 15% (95% CI, -3% to 30%; <i>P</i> = .10). The trial conducted a pre-specified analysis in which cases considered prevalent based on CA-125 levels at baseline were omitted. This subset analysis found a significant reduction in mortality of 20% (95% CI, -2% to 40%, <i>P</i> = .021), compared with observation.[<a class="bk_pop" href="#CDR0000062760_rl_7_11">11</a>]</p><p id="CDR0000062760__187">A <i>post hoc</i> nested study was conducted within the PLCO trial to determine if the use of ROCA could potentially improve the identification of early-stage (stage I and stage II) ovarian cancer.[<a class="bk_pop" href="#CDR0000062760_rl_7_29">29</a>] The study evaluated the potential impact under two scenarios: best case and stage shift. Best-case scenario assumed that all cancers that would have been detected earlier with ROCA than with single-threshold CA-125 concentrations would have avoided mortality. The stage-shift scenario applied the observed PLCO early-stage survival rates to cases detected at an earlier stage with ROCA. The risk of death from ovarian cancer with ROCA was lower but estimates were not statistically significant (relative risk [RR] of 0.90 for best-case scenario [95% CI, 0.69–1.17] and RR of 0.95 for stage-shift scenario [95% CI, 0.74–1.23]).</p><p id="CDR0000062760__144">Another retrospective study using annual CA-125 concentrations from the PLCO trial examined the potential impact of parametric empirical Bayes (PEB) longitudinal algorithm for the earlier detection of 44 incident ovarian cancers identified in the PLCO trial. Setting the specificity at 99%, PEB signaled “abnormal” CA-125 concentrations on average 10 months earlier than with the single-threshold cutpoint.[<a class="bk_pop" href="#CDR0000062760_rl_7_30">30</a>] Whether this translated into a mortality benefit could not be determined.</p><p id="CDR0000062760__145">CA-125 velocity has also been examined using a multiple logistic regression model within the PLCO trial as a predictor for the development of ovarian cancer.[<a class="bk_pop" href="#CDR0000062760_rl_7_31">31</a>] Both CA-125 velocity and time intervals between screening tests were associated with the development of ovarian cancer. The risk of ovarian cancer increased as velocity (measured as U/mL per month) increased, and the risk of ovarian cancer decreased when the time intervals between screening tests increased.</p></div></div><div id="CDR0000062760__155"><h3>Other Potential Markers</h3><p id="CDR0000062760__156">Research continues to find other biomarkers that either alone or in combination with CA-125 concentrations may lead to the early detection of ovarian cancer. A panel of biomarkers that included CA-125, HE4, transthyretin, CA15.3, and CA72.4 was evaluated using specimens assembled from multiple cohort and randomized trials, including the PLCO trial.[<a class="bk_pop" href="#CDR0000062760_rl_7_23">23</a>] The phase II and III biomarker studies concluded that CA-125 remained the “single-best biomarker” for ovarian cancer. Another retrospective study, nested within the PLCO trial and included 118 ovarian cancer cases and 8 controls per case, evaluated seven proteomic biomarkers (apolipoprotein A1, truncated transthyretin, transferrin, hepcidin, beta-2 microglobulin, connective tissue activating protein III, and inter-alpha-trypsin inhibitor heavy-chain) in addition to CA-125.[<a class="bk_pop" href="#CDR0000062760_rl_7_32">32</a>] The addition of the seven protein biomarkers to CA-125 did not improve the sensitivity beyond the use of CA-125 levels alone. This contrasted with this same group’s preliminary evaluation of these markers using postdiagnostic rather than prediagnostic blood samples.[<a class="bk_pop" href="#CDR0000062760_rl_7_33">33</a>]</p></div><div id="CDR0000062760__148"><h3>Harms of Screening</h3><p id="CDR0000062760__149">The PLCO trial provides the most reliable data to date on screening-related harms.[<a class="bk_pop" href="#CDR0000062760_rl_7_24">24</a>] The rate of minor complications associated with CA-125 and TVU, such as bruising or fainting, occurred at a rate of 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with TVU. Major complications associated with the diagnostic procedures among women diagnosed with ovarian cancer included infections, blood loss, bowel injury, and cardiovascular events. At least one major complication was reported among 52% of women diagnosed in the usual-care group and 45% among women diagnosed with ovarian cancer in the screened group. </p><p id="CDR0000062760__150">False-positive tests occurred among 3,285 women, translating to a rate of about 5% at each screening round. Most false-positive tests (60%) resulted from TVU. Of the 3,285 women with false-positive results, 33% underwent surgery. Of the 1,080 women who underwent surgery, 15% had 222 major complications, for a rate of 20.6 complications per 100 surgical procedures.[<a class="bk_pop" href="#CDR0000062760_rl_7_24">24</a>]</p><p id="CDR0000062760__151">Women in the intervention group were more likely to have had an oophorectomy than those in the control group. Rates of oophorectomy were 85.7 per 10,000 person-years in the screened group, compared with 64.2 per 10,000 person-years in the usual-care group (rate ratio, 1.33; 95% CI, 1.24–1.43).[<a class="bk_pop" href="#CDR0000062760_rl_7_24">24</a>]</p></div><div id="CDR0000062760_rl_7"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062760_rl_7_1">American Cancer Society: Cancer Facts and Figures 2017. Atlanta, Ga: American Cancer Society, 2017. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed March 7, 2018.</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_2">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review, 1975-2012. Bethesda, Md: National Cancer Institute, 2015. <a href="http://seer.cancer.gov/csr/1975_2012/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Also available online</a>. Last accessed March 29, 2018.</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_3">Prat J: Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 460 (3): 237-49, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22322322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22322322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_4">Cramer DW: The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am 26 (1): 1-12, 2012. [<a href="/pmc/articles/PMC3259524/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3259524</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22244658" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22244658</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_5">Hunn J, Rodriguez GC: Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 55 (1): 3-23, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22343225" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22343225</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_6">Goff BA, Mandel LS, Melancon CH, et al.: Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291 (22): 2705-12, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15187051" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15187051</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_7">Lim AW, Mesher D, Gentry-Maharaj A, et al.: Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. J Natl Cancer Inst 104 (2): 114-24, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22247022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22247022</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_8">Smith LH, Oi RH: Detection of malignant ovarian neoplasms: a review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. Obstet Gynecol Surv 39 (6): 313-28, 1984. [<a href="https://pubmed.ncbi.nlm.nih.gov/6374536" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6374536</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_9">Hall DJ, Hurt WG: The adnexal mass. J Fam Pract 14 (1): 135-40, 1982. [<a href="https://pubmed.ncbi.nlm.nih.gov/7054360" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7054360</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_10">Higgins RV, van Nagell JR Jr, Woods CH, et al.: Interobserver variation in ovarian measurements using transvaginal sonography. Gynecol Oncol 39 (1): 69-71, 1990. [<a href="https://pubmed.ncbi.nlm.nih.gov/2227575" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2227575</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_11">Jacobs IJ, Menon U, Ryan A, et al.: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387 (10022): 945-56, 2016. [<a href="/pmc/articles/PMC4779792/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4779792</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26707054" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26707054</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_12">Sharma A, Apostolidou S, Burnell M, et al.: Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol 40 (3): 338-44, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22911637" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22911637</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_13">Bast RC Jr, Feeney M, Lazarus H, et al.: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 (5): 1331-7, 1981. [<a href="/pmc/articles/PMC370929/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC370929</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7028788" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7028788</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_14">Bast RC Jr, Klug TL, St John E, et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 (15): 883-7, 1983. [<a href="https://pubmed.ncbi.nlm.nih.gov/6310399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6310399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_15">Jacobs I, Stabile I, Bridges J, et al.: Multimodal approach to screening for ovarian cancer. Lancet 1 (8580): 268-71, 1988. [<a href="https://pubmed.ncbi.nlm.nih.gov/2893084" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2893084</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_16">Buys SS, Partridge E, Greene MH, et al.: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193 (5): 1630-9, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16260202" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16260202</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_17">Gohagan JK, Levin DL, Prorok JC, et al., eds.: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6 suppl): 249S-406S, 2000.</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_18">Jacobs I, Bast RC Jr: The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4 (1): 1-12, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2651469" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2651469</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_19">Niloff JM, Knapp RC, Schaetzl E, et al.: CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 64 (5): 703-7, 1984. [<a href="https://pubmed.ncbi.nlm.nih.gov/6208522" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6208522</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_20">Haga Y, Sakamoto K, Egami H, et al.: Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci 292 (1): 25-9, 1986. [<a href="https://pubmed.ncbi.nlm.nih.gov/3521278" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3521278</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_21">Zurawski VR Jr, Orjaseter H, Andersen A, et al.: Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 42 (5): 677-80, 1988. [<a href="https://pubmed.ncbi.nlm.nih.gov/3182103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3182103</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_22">Helzlsouer KJ, Bush TL, Alberg AJ, et al.: Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 269 (9): 1123-6, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8433467" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8433467</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_23">Cramer DW, Bast RC Jr, Berg CD, et al.: Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4 (3): 365-74, 2011. [<a href="/pmc/articles/PMC3085251/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3085251</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21372036" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21372036</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_24">Buys SS, Partridge E, Black A, et al.: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305 (22): 2295-303, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21642681" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21642681</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_25">Pinsky PF, Yu K, Kramer BS, et al.: Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. Gynecol Oncol 143 (2): 270-275, 2016. [<a href="/pmc/articles/PMC5077651/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5077651</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27615399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27615399</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_26">Partridge E, Kreimer AR, Greenlee RT, et al.: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113 (4): 775-82, 2009. [<a href="/pmc/articles/PMC2728067/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2728067</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19305319" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19305319</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_27">Bodelon C, Pfeiffer RM, Buys SS, et al.: Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis. J Natl Cancer Inst 106 (10): , 2014. [<a href="/pmc/articles/PMC4168310/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4168310</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25217774" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25217774</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_28">Kobayashi H, Yamada Y, Sado T, et al.: A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 18 (3): 414-20, 2008 May-Jun. [<a href="https://pubmed.ncbi.nlm.nih.gov/17645503" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17645503</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_29">Pinsky PF, Zhu C, Skates SJ, et al.: Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer 132 (9): 2127-33, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23065684" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23065684</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_30">Drescher CW, Shah C, Thorpe J, et al.: Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol 31 (3): 387-92, 2013. [<a href="/pmc/articles/PMC3732015/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3732015</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23248253" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23248253</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_31">Xu JL, Commins J, Partridge E, et al.: Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol 125 (1): 70-4, 2012. [<a href="/pmc/articles/PMC3303942/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3303942</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22198243" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22198243</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_32">Moore LE, Pfeiffer RM, Zhang Z, et al.: Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 118 (1): 91-100, 2012. [<a href="/pmc/articles/PMC3385508/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3385508</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21717433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21717433</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062760_rl_7_33">Clarke CH, Yip C, Badgwell D, et al.: Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122 (3): 548-53, 2011. [<a href="/pmc/articles/PMC3152646/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3152646</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21708402" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21708402</span></a>]</div></li></ol></div></div><div id="CDR0000062760__23"><h2 id="_CDR0000062760__23_">Changes to This Summary (02/03/2017)</h2><p id="CDR0000062760__25">The PDQ cancer information summaries are reviewed regularly and updated as
|
|
new information becomes available. This section describes the latest
|
|
changes made to this summary as of the date above.</p><p id="CDR0000062760__200"><b><a href="#CDR0000062760__7">Description of the Evidence</a></b></p><p id="CDR0000062760__205">Updated <a href="#CDR0000062760__108">statistics</a> with estimated new cases and deaths for 2017 (cited American Cancer Society as reference 1).</p><p id="CDR0000062760__206">Revised <a href="#CDR0000062760__122">text</a> to state that elevated cancer antigen 125 levels are not specific to ovarian cancer and have been observed in patients with nongynecological cancers, endometriosis, liver disease, congestive heart failure, pleural or peritoneal fluid accumulation, and in the first trimester of pregnancy (cited Jacobs et al. as reference 18).</p><p id="CDR0000062760__disclaimerHP_3">This summary is written and maintained by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Screening and Prevention Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062760__AboutThis_1">About This PDQ Summary</a> and <a href="http://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
|
|
</p></div><div id="CDR0000062760__AboutThis_1"><h2 id="_CDR0000062760__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062760__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062760__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian, fallopian tube, and primary peritoneal cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062760__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062760__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Screening and Prevention Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062760__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062760__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062760__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p id="CDR0000062760__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062760__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062760__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <a href="/books/n/pdqcis/CDR0000304747/">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062760__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062760__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062760__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062760__AboutThis_15">PDQ® Screening and Prevention Editorial Board. PDQ Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/types/ovarian/hp/ovarian-screening-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/types/ovarian/hp/ovarian-screening-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 26389336]</p><p id="CDR0000062760__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062760__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062760__AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062760__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062760__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK65898</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26389336" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">26389336</a></span></div></div></div>
|
|
|
|
</div>
|
|
|
|
<!-- Custom content below content -->
|
|
<div class="col4">
|
|
|
|
</div>
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<!-- Custom contetnt below bottom nav -->
|
|
<div class="col5">
|
|
|
|
</div>
|
|
</div>
|
|
|
|
<div id="rightcolumn" class="four_col col last">
|
|
<!-- Custom content above discovery portlets -->
|
|
<div class="col6">
|
|
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK65898&db=books">Share</a></div>
|
|
|
|
</div>
|
|
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65898.5/?report=reader">PubReader</a></li><li><a href="/books/NBK65898.5/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK65898" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK65898" style="display:none" title="Cite this Page"><div class="bk_tt">PDQ Screening and Prevention Editorial Board. Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®): Health Professional Version. 2017 Feb 3. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></div></div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Version History</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter shutter_closed" title="Show/hide content" remembercollapsed="true" pgsec_name="version_history" id="Shutter"></a></div><div class="portlet_content" style="display: none;"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><span class="bk_col_itm"><a href="/books/NBK65898.23/">NBK65898.23</a></span> December 11, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65898.22/">NBK65898.22</a></span> May 24, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65898.21/">NBK65898.21</a></span> October 26, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK65898.20/">NBK65898.20</a></span> March 23, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK65898.19/">NBK65898.19</a></span> February 10, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK65898.18/">NBK65898.18</a></span> November 10, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65898.17/">NBK65898.17</a></span> August 31, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65898.16/">NBK65898.16</a></span> June 23, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65898.15/">NBK65898.15</a></span> May 12, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65898.14/">NBK65898.14</a></span> June 11, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK65898.13/">NBK65898.13</a></span> March 26, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK65898.12/">NBK65898.12</a></span> December 17, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65898.11/">NBK65898.11</a></span> April 20, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65898.10/">NBK65898.10</a></span> February 21, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65898.9/">NBK65898.9</a></span> November 14, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65898.8/">NBK65898.8</a></span> March 22, 2019</li><li><span class="bk_col_itm"><a href="/books/NBK65898.7/">NBK65898.7</a></span> June 14, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65898.6/">NBK65898.6</a></span> April 6, 2018</li><li><span class="bk_col_itm">NBK65898.5</span> February 3, 2017 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK65898.4/">NBK65898.4</a></span> November 18, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65898.3/">NBK65898.3</a></span> October 21, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65898.2/">NBK65898.2</a></span> March 4, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65898.1/">NBK65898.1</a></span> March 27, 2015</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#CDR0000062760__1" ref="log$=inpage&link_id=inpage">Overview</a></li><li><a href="#CDR0000062760__7" ref="log$=inpage&link_id=inpage">Description of the Evidence</a></li><li><a href="#CDR0000062760__23" ref="log$=inpage&link_id=inpage">Changes to This Summary (02/03/2017)</a></li><li><a href="#CDR0000062760__AboutThis_1" ref="log$=inpage&link_id=inpage">About This PDQ Summary</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related publications</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK66055/">Patient Version</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=2823854" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=2823854" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389359" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Prevention (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Prevention (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Screening and Prevention Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389443" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28876831" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thyroid Cancer Screening (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Thyroid Cancer Screening (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Screening and Prevention Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389383" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Prostate Cancer Screening (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Prostate Cancer Screening (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Screening and Prevention Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389300" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Skin Cancer Screening (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Skin Cancer Screening (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Screening and Prevention Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=26389336" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=26389336" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c98d9ff4a390645eddc663">Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®) - PDQ Ca...</a><div class="ralinkpop offscreen_noflow">Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c98d94ab82281a80e33ecb">Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Screening (PDQ®) - PDQ C...</a><div class="ralinkpop offscreen_noflow">Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Screening (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_qry two_line"><a class="htb" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c98d7fa68b6b5afc18aee9">PMC Links for Books (Select 2826666) <span class="number">(38)</span></a><div class="tertiary">PMC</div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=67c98d7ea68b6b5afc18a681">Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries</a><div class="ralinkpop offscreen_noflow">Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
|
|
|
<!-- Custom content below discovery portlets -->
|
|
<div class="col7">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
<!-- Custom content after all -->
|
|
<div class="col8">
|
|
|
|
</div>
|
|
<div class="col9">
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
|
<script type="text/javascript">
|
|
(function($){
|
|
$('.skiplink').each(function(i, item){
|
|
var href = $($(item).attr('href'));
|
|
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
|
$(item).on('click', function(event){
|
|
event.preventDefault();
|
|
$.scrollTo(href, 0, {
|
|
onAfter: function(){
|
|
href.focus();
|
|
}
|
|
});
|
|
});
|
|
});
|
|
})(jQuery);
|
|
</script>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<div class="footer" id="footer">
|
|
<section class="icon-section">
|
|
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
|
<div class="grid-container container">
|
|
<div class="icon-section_container">
|
|
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11 {
|
|
fill: #737373;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>Twitter</title>
|
|
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>Facebook</title>
|
|
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>LinkedIn</title>
|
|
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11,
|
|
.cls-12 {
|
|
fill: #737373;
|
|
}
|
|
|
|
.cls-11 {
|
|
fill-rule: evenodd;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>GitHub</title>
|
|
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
|
</path>
|
|
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
|
</path>
|
|
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
|
</path>
|
|
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
|
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
|
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
|
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
|
<title>NCBI Insights Blog</title>
|
|
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
|
</svg>
|
|
</a>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
|
|
<section class="container-fluid bg-primary">
|
|
<div class="container pt-5">
|
|
<div class="row mt-3">
|
|
<div class="col-lg-3 col-12">
|
|
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
|
<ul class="list-inline social_media">
|
|
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st20 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st30 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Twitter</title>
|
|
<g>
|
|
<g>
|
|
<g>
|
|
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
|
</g>
|
|
</svg></a></li>
|
|
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
|
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st10 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st110 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Facebook</title>
|
|
<g>
|
|
<g>
|
|
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
|
</svg>
|
|
</a></li>
|
|
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<title>Youtube</title>
|
|
<style type="text/css">
|
|
.st4 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
|
|
.st5 {
|
|
fill: #FFFFFF;
|
|
}
|
|
</style>
|
|
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
|
<g transform="translate(0,-952.36218)">
|
|
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
|
</g>
|
|
</svg></a></li>
|
|
</ul>
|
|
</div>
|
|
<div class="col-lg-3 col-12">
|
|
<p class="address_footer text-white">National Library of Medicine<br />
|
|
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
|
Bethesda, MD 20894</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
|
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
|
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
|
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
|
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-12 centered-lg">
|
|
<nav class="bottom-links">
|
|
<ul class="mt-3">
|
|
<li>
|
|
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
|
</li>
|
|
</ul>
|
|
</nav>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK65898&ncbi_domain=pdqcis&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK65898.5/&ncbi_pagename=Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |